GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » EV-to-EBIT

Beijing Luzhu Biotechnology Co (HKSE:02480) EV-to-EBIT : -23.51 (As of May. 12, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Beijing Luzhu Biotechnology Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Beijing Luzhu Biotechnology Co's Enterprise Value is HK$6,389.09 Mil. Beijing Luzhu Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-271.81 Mil. Therefore, Beijing Luzhu Biotechnology Co's EV-to-EBIT for today is -23.51.

The historical rank and industry rank for Beijing Luzhu Biotechnology Co's EV-to-EBIT or its related term are showing as below:

HKSE:02480' s EV-to-EBIT Range Over the Past 10 Years
Min: -46.93   Med: 0   Max: 0
Current: -23.51

HKSE:02480's EV-to-EBIT is ranked worse than
100% of 433 companies
in the Biotechnology industry
Industry Median: 9.43 vs HKSE:02480: -23.51

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Beijing Luzhu Biotechnology Co's Enterprise Value for the quarter that ended in Jun. 2023 was HK$7,222.26 Mil. Beijing Luzhu Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-271.81 Mil. Beijing Luzhu Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -3.76%.


Beijing Luzhu Biotechnology Co EV-to-EBIT Historical Data

The historical data trend for Beijing Luzhu Biotechnology Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Luzhu Biotechnology Co EV-to-EBIT Chart

Beijing Luzhu Biotechnology Co Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBIT
- - -19.90

Beijing Luzhu Biotechnology Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT - - - - -

Competitive Comparison of Beijing Luzhu Biotechnology Co's EV-to-EBIT

For the Biotechnology subindustry, Beijing Luzhu Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Luzhu Biotechnology Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Luzhu Biotechnology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Beijing Luzhu Biotechnology Co's EV-to-EBIT falls into.



Beijing Luzhu Biotechnology Co EV-to-EBIT Calculation

Beijing Luzhu Biotechnology Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=6389.093/-271.81
=-23.51

Beijing Luzhu Biotechnology Co's current Enterprise Value is HK$6,389.09 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Beijing Luzhu Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-271.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Luzhu Biotechnology Co  (HKSE:02480) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Beijing Luzhu Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 ) =EBIT / Enterprise Value (Q: Jun. 2023 )
=-271.81/7222.256
=-3.76 %

Beijing Luzhu Biotechnology Co's Enterprise Value for the quarter that ended in Jun. 2023 was HK$7,222.26 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Beijing Luzhu Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-271.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Luzhu Biotechnology Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Beijing Luzhu Biotechnology Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Luzhu Biotechnology Co (HKSE:02480) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN
Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Its clinical-stage product candidates comprise one vaccine candidate, LZ901 and two antibody injection product candidates, including K3 and K193. LZ901 is our Core Product.

Beijing Luzhu Biotechnology Co (HKSE:02480) Headlines

No Headlines